Diabetes is on the rise worldwide, with a global prevalence in adults in 2017 being 8.8% of the world population, with the anticipation of a further increase to 9.9% by 2045. In total numbers, this reflects a population of 424.9 million people with diabetes worldwide in 2017, with an estimate of a 48% increase to 628.6 million people by 2045. Depending on age, global diabetes prevalence is about 5%, 10%, 15% and close to 20%, respectively, for the age groups 35-39, 45-49, 55-59 and 65-69 years. On a global scale, diabetes hits particularly 'middle aged' people between 40 and 59 years, which causes serious economic and social implications. Furthermore, diabetes affects especially low and middle income countries, as 77% of all people with diabetes worldwide live in those countries. In addition to overt diabetes, an estimated 352.1 million people worldwide are at risk of diabetes, i.e. have defined pre-diabetes, a figure which is anticipated to rise to 531.6 million by 2045. Some 70-75% of all patients with established coronary artery disease, e.g. with acute myocardial infarction, show concomitant diabetes or abnormal glucose regulation, i.e. close to 50% have overt diabetes, with as many as 20% of those being undiagnosed and another 25% having pre-diabetes.
Introduction
Diabetes mellitus can affect people in many ways, ranging from acute threats due to decompensated metabolism with severe hyperglycaemic hyperosmolar coma, ketoacidosis, or severe hypoglycaemia, to longer-term serious complications at the large and small arterial blood vessels as well as at the nervous system, and to lifelong challenges to the quality of life due to a whole array of psychosocial problems. 1 Both the United Nations and the World Health Organization (WHO), therefore, have focused on diabetes as a major global health concern in view of the enormous worldwide epidemic of this, perhaps the most important non-communicable global disease fostered by an unhealthy modern lifestyle. 2, 3 In terms of cardiovascular risk, diabetes and cardiovascular disease have been described as 'two bad companions' or the two sides of the same coin, with the majority of people with diabetes dying from cardiovascular causes and, vice versa, the majority of contemporary people with cardiovascular complications also having diabetes or pre-diabetes. 1, [4] [5] [6] Accordingly, joint guidelines have been launched first by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) 4, 5 and followed by other interdisciplinary health organisations worldwide. 7 The present paper gives a brief overview of the current and expected future global burden of diabetes mellitus as part of a supplement issue of this journal dedicated to the topic 'diabetes and cardiovascular risk'.
Diabetes prevalence of the adult population
According to the most recent 8th edition of the International Diabetes Federation (IDF) Diabetes Atlas 2017, diabetes is on the rise across the world. 8 Global diagnostic criteria for diabetes mellitus have been harmonised between WHO, IDF and the American Diabetes Association (ADA) and are depicted in Table 1 . [8] [9] [10] Based on these criteria, the current global diabetes prevalence in 2017 was 8.8% (95% confidence interval (CI) 7.2-11.3%), standardised for the age group 20-79 years, with a further increase expected to 9.9% (95% CI 7.5-12.7%) by the year 2045. In total numbers, this reflects a population of 424.9 million (95% CI 346.4-545.4 million) people with diabetes worldwide in 2017, with an estimate of a 48% increase to 628.6 million people (95% CI 477.0-808.7 million) for the year 2045. Global numbers of diabetes prevalence have continuously risen from 151 million in 2000, when the IDF Diabetes Atlas first was launched, to 285 million in 2009 and to 382 million in 2013. The figures given in the IDF atlas fit well with the estimates of an international consortium reporting worldwide trends in diabetes since 1980 based on a pooled analysis of 751 population-based studies with 4Á4 million participants. 11 According to this group global age-standardised diabetes prevalence increased from 4.3% (95% CI 2.4-7.0) in 1980 to 9.0% (7.2-11.1) in 2014 in men, and from 5.0% (2.9-7.9) to 7.9% (6.4-9.7) in women. So, as in the IDF statistics, diabetes more or less equally affects both sexes, with men being affected slightly more compared to women in younger age groups and women surpassing men at higher age groups. 8, 11 Moreover, it was estimated by the international consortium that the number of adults with diabetes in the world had increased from 108 million in 1980 to 422 million in 2014. The group further determined that 28.5% of the increase was due to the rise in true prevalence, 39.7% due to population growth and ageing, and 31.8% due to the interaction of these two factors. Besides the growth and aging of the world population in general, the global obesity epidemic has turned out to be a key factor for the rise of diabetes incidence, together with a prolonged life expectancy due to the immense progress of multifactorial cardiovascular risk management and successful revascularisation therapy of people with diabetes also contributing to the expansion of the worldwide diabetes population. 1, 6, [12] [13] [14] [15] [16] Based on the estimates of the international consortium, 11 Table 2 lists the top 10 countries in terms of millions of adults with diabetes mellitus between 1980 and 2014, indicating a shift away from European countries and towards Asian countries, Egypt and Mexico, countries with a high population growth in recent decades.
The WHO Global Health Observatory data 2016 17 indicate that the prevalence of obesity and overweight is particularly high in the United States, Gulf countries, Maghreb countries and Turkey, especially in women, with more than 30% of the adult population being obese (body mass index (BMI) of 30 kg body weight/ m 2 height or higher) and about two-thirds of the population having a BMI of above 25 kg/m 2 , i.e. having overweight or obesity. These countries and regions are also hot spots of the diabetes epidemic. Most Wider fasting plasma glucose criteria of ADA for IFG: 5.6-6.9 mmol/L (100-125 mg/dL) Additional or deviant criteria provided by ADA. 10 HbA1c criteria for pre-diabetes (IGT or IFG): 39-47 mmol/mol (5.7-6.4%). Wider fasting plasma glucose criteria for IFG: 5.6-6.9 mmol/L (100-125 mg/dL).
European countries range in the mid 20% for obesity and high 50% for either being obese or overweight. On the other hand, countries around the Indian subcontinent, China and other oriental Asian countries show the lowest prevalence of obesity and overweight (obesity rates below 10% of the adult population). Nevertheless, those regions exhibit the highest incidence and prevalence rates of diabetes in recent years ( Table 2) , probably referring to a special diabetes phenotype, with low insulin reserve and high insulin resistance in the context of a westernised lifestyle. 1 For example, in China, 10.9% of the adult population was found to have diabetes, i.e. approximately 100 million people, with about two-thirds of this population being undiagnosed. 18 Globally, every other person with diabetes is estimated to be undiagnosed, in European countries the figure for undiagnosed diabetes ranges between 20% and 35%. 8 Depending on age, global diabetes prevalence is about 5%, 10%, 15% and close to 20%, respectively, for the age groups 35-39, 45-49, 55-59 and 65-69 years. 8 On a global scale, diabetes hits particularly 'middle aged' people between 40 and 59 years of age, which has serious economic and social implications. Furthermore, diabetes affects especially low and middle income countries, as 77% of all people with diabetes worldwide live in those countries. Figure 1 summarises the growing burden of the global diabetes epidemic. 8, 11, 12, 19 Diabetes types, subforms and pre-diabetes Diabetes prevalence numbers are largely determined by people with type 2 diabetes mellitus (T2DM), which comprises about 90% of the total population. These individuals are characterised by various degrees of relative insulin deficiency in conjunction with a wide spectrum of insulin resistance. About 5% of the total diabetes population represents monogenic forms of diabetes, such as various subtypes of maturity-onset diabetes of the young and other rare genetic conditions, another 5% encompass subforms of immune-mediated type 1 diabetes, with a pronounced if not absolute insulin deficit in the long run. 1, 8 Reflecting the enormous therapeutic progress in the past 30 years, many people affected with type 1 diabetes now are able to live for Adapted from NCD Risk Factor Collaboration (NCD-RisC). 11 almost a normal life span, although the disease usually starts at a young age, i.e. in children and adolescents.
For the age group 0-19 years, the IDF Diabetes Atlas 2017 estimates 1,106,500 people globally with type 1 diabetes, with an annual incidence of 132,600 newly diagnosed cases. 8 Compared to type 1 diabetes, numbers of T2DM in adolescents and young adults are still small on a global scale, although rapidly increasing as a result of the worldwide obesity epidemic, especially also in minority groups in the USA. 8, 20, 21 This emerging epidemic in underprivileged young people of non-European descent may pose a big burden in the near future, as it is carried by a severe progressive form of diabetes that frequently presents with complications, responds poorly to treatment and results in rapid progression of microvascular and macrovascular complications. 20, 21 In addition to overt diabetes, the IDF atlas ( Figure 1 ) estimates another 352.1 million (95% CI 233.5-577.3 million) people worldwide to have a prestage of diabetes, referred to as impaired glucose tolerance (IGT), a figure which is anticipated to rise to 531.6 million (95% CI 353.8-883.9 million) in 2045. 8 In the latter group, the manifestation of overt diabetes could actually be prevented in most people, along with most of the severe microvascular and macrovascular complications, by appropriate lifestyle interventions.
Most forms of diabetes (and pre-diabetes) have a strong genetic background or predisposition enabling environmental and modifiable factors, such as overweight and obesity, physical inactivity, but also triggers of autoimmune processes to precipitate the manifestation of the disease. 1, 8 The genetic background is rather complex and comprises at present several hundreds of identified gene loci, many of which still have unknown functions. 1 Although considerable attempts are ongoing to differentiate specific subphenotypes of diabetes with different course and prognosis, genetic factors -with a few exceptions -have not turned out to be helpful in this process. 8 Empirically, however, monozygotic twins have been shown to be identical for T2DM in more than 90% of cases as compared to about 30% of cases for type 1 diabetes. 1, 8 Prevalence of diabetes and pre-diabetes in individuals with CAD Overall, 70-75% of all patients with established coronary artery disease (CAD), e.g. with acute myocardial infarction, show concomitant diabetes or significant perturbations of glucose homeostasis. 4, 5, 22, 23 With a growing tendency, more than 30% of contemporary patients with CAD have known coexisting diabetes. In addition, 10-20% of those patients with CAD have previously undiagnosed diabetes and another quarter IGT or pre-diabetes. [22] [23] [24] Similar figures have been found in patients enrolled in recent heart failure trials, e.g. in PARADIGM HF, with 35% of patients with known diabetes, an additional 13% with a haemoglobin A1c (HbA1c) value diagnostic for diabetes, and another 25% having a HbA1c value in the pre-diabetic range. 25 In those with established CAD, there is ample evidence that the information derived by an oral glucose tolerance test (OGTT) identifies the largest number of undiagnosed people with diabetes and that it is the only test that discloses the presence of IGT. 4, 5, [22] [23] [24] The ESC guidelines, in collaboration with EASD 2019, therefore, recommend that screening for potential T2DM in patients with cardiovascular disease including CAD is initiated with HbA1c and fasting plasma glucose (FPG), and that a OGTT is added, if HbA1c and FPG are inconclusive. 5 These recommendations are based on findings such as in EUROASPIRE IV, in which 4004 patients with CAD without known diabetes have been screened for undiagnosed diabetes, using all screening tests together (determinations of FPG, 2-hour post-load glucose (2hPG) and HbA1c). 24 Of those, 1158 (29%) had undetected diabetes. The proportion identified by FPG was 75%, by 2hPG 40%, by HbA1c 17%, by FPG plus HbA1c 81% and by OGTT (FPG þ 2hPG) 96%. In addition, when 4422 patients with CAD without known glucose perturbations were screened in EUROASPIRE V, 41% were dysglycaemic (IGT 25% and new diabetes 16%). The proportion with diabetes identified by HbA1c was 19%, by FPG 58% and with OGTT 91%. Thus, HbA1c only contributed a small proportion above that disclosed by FPG plus 2hPG. 26 These and other data, 26, 27 although not undisputed, 28 favour the use of OGTT, if the ambition is to disclose as many dysglycaemic patients as possible in high-risk populations with established CAD for appropriate risk stratification and treatment with glucose-lowering agents that also reduce mortality and cardiovascular disease (Figure 2 ). 29 This approach contrasts with the regular diagnostic algorithm in the general population, which involves using risk score questionnaires for screening and the use of HbA1c measurements for diagnosis. 4, 5, 30 It has been known for some time that CAD may be present at the diagnosis of T2DM, with some 40% of patients showing CAD-related ECG changes. 31 The reasons for this observation seem to be complex and include, for example, a potential long lag time between the clinical onset and diagnosis of T2DM or clustering of other cardiovascular risk factors such as hypertension or dyslipidemia with T2DM. 31, 32 This latter phenomenon is often referred to as the metabolic syndrome and originates from the dysglycemic diabetic pre-state below the threshold of T2DM, i.e. also people with IGT which mostly remains undiagnosed are at increased cardiovascular risk. Epidemiological evaluations have shown that the risk of cardiovascular events may be several fold increased up to 15 years prior to the diagnosis of diabetes. 32 
Excess mortality
Although mortality and vascular complication rates worldwide have been markedly reduced and indeed cut by half over the past three decades in people with diabetes, 6,19 a relative twofold increased mortality risk (both for all-cause and cardiovascular mortality) has remained for people with T2DM despite all the progress in primary and secondary prevention, with even a higher excess risk for people with type 1 diabetes. 6, 12, 19 Depending on the age at onset of diabetes and the overall cardiovascular risk factor control, the loss of life can be up to 30% of the further regular life expectancy without diabetes. 12, 33 These notions have primarily been derived from high income countries such as the USA or Sweden; looking at low income countries, a more than sevenfold higher absolute cardiovascular mortality risk for people with diabetes has been reported, probably due to very low healthcare resources in those countries. 34 According to the estimated IDF statistics, presently every 6 seconds someone will die from diabetes or its complications, with 50% of those deaths (4 million in total per year) occurring under the age of 60 years. 8 As already mentioned, excessive death rates not only relate to cardiovascular causes, but also to noncardiovascular causes such as cancer, renal disease, liver disease, pneumonia, septicaemia and other infections. 1, 6, 12, 19, 35 In contemporary global cohorts of T2DM, e.g. as studied in the TECOS trial, more than 50% of all deaths are due to cardiovascular causes, with sudden death being the most common cause, followed by combined death from myocardial infarction or stroke, and death from heart failure. 36 Particularly high death rates are unfortunately still reported for young-onset type 1 diabetes (age group 0-10 years). They showed hazard ratios of 4.11 (95% CI 3.24-5.22) for all-cause mortality, 7.38 (3.65-14.94) for cardiovascular mortality and 3.96 (3.6-5.11) for non-cardiovascular mortality in a recent assessment based on the National Diabetes Register in Sweden. 35 Similar to HbA1c values in the pre-diabetic range, the state of IGT and -to a lesser degree -the state of impaired fasting glucose were found to be highly predictive not only for cardiovascular events and mortality, but also for all-cause mortality, and nearly to the same extent as in people with overt diabetes. 37, 38 The association with fasting glucose may even show a J-type curve, in that very low glucose concentrations at the far low end are also associated with increased all-cause and cardiovascular mortality. 12 Very low fasting glucose, however, may not necessarily be a causative factor for cardiovascular mortality, but may rather be a surrogate of high cardiovascular risk as associated with confounding comorbidities and diseases, perhaps alluding to reverse epidemiology.
Healthcare expenditure and health economics related to diabetes
Due to the large numbers of people with the disease as well as the huge burden of its micro and macrovascular complications, diabetes globally has an enormous economic impact on countries, their healthcare systems, and not least on the individuals with diabetes and their families. According to the IDF atlas 2017, the global healthcare expenditure for diabetes has risen from US$232b in 2007 to US$727 in 2017 for those aged 20-79 years -a more than threefold rise within 10 years and the expectation of a further increase in the coming years. 8 The top three countries with the highest expenditure, i.e. the USA, China and Germany, spend about two-thirds of the total amount, alluding to big differences across countries worldwide. Mean per capita spending per year was highest in the USA, with over US$11,000, followed by eight European countries, with an amount spent between US$6000 and US$9000. At the other end of the spectrum reside Africa, with far below US$1000 spent per person with diabetes a year, and South-East Asia, with an amount below US$2000. 8 One recent US study estimated that, in comparison with individuals without diabetes, individuals with diabetes had more than double the mean unadjusted costs (US$5058 vs. US$12,180). This translated to people with diabetes having US$2558 significantly higher direct incremental costs compared with those without diabetes after adjustment of confounders. 39 Another US study estimated that the medical costs of diabetes were two to eight times higher than other chronic conditions. 40 Higher rates of inpatient hospitalisation and diabetes-related complications account for most of the costs related to diabetes. 41, 42 Another study estimated that hospital inpatient stay, prescription medicine and office visits were 2.6, 3.4 and 1.9 times higher in people with diabetes, respectively, compared with people without diabetes. 43 In terms of the percentage spent globally of the healthcare budget for people with diabetes, the list is led by the Gulf countries, with 17%, followed by North America and the Caribbean with 14%, the hot spots of the global obesity-driven diabetes epidemic. These figures contrast markedly with Africa, where only 6% of the healthcare budget is spent for people with diabetes. 8 The age group with the highest expenditure worldwide is the age group 60-69 years, with its large numbers of people with diabetes and high frequencies of advanced diabetes-related complications. 8 In terms of the absolute economic burden related to diabetes worldwide it has been estimated that it will increase from US$1.3t in 2015 to around US$2.2-2.5t by 2030, translating to a 88% increase in cost as a share of global gross domestic product (GDP) from 1.8% in 2015 to 2.2%. 43 These costs of diabetes include both direct costs of medical care and also indirect costs through loss of productivity or earnings. 44 There are therefore calls for policy-makers and international health organisations to take urgent action to prepare health and social care organisations to mitigate the estimated rise in costs. 43 
Perspectives
Although the diabetes prevalence is already very high worldwide, i.e. nearly 9% of the adult population, a further 50% increase of absolute numbers is anticipated over the next decades along with a further expansion of the associated increased cardiovascular risk and the related challenges to many more people. Developing countries and underprivileged minorities seem to face a particularly high burden, unless healthcare systems can be adapted in a more appropriate way to overcome these challenges. As about 50% of all people with diabetes worldwide are undiagnosed, the best healthcare policies comprise early targeting of people at increased diabetes risk, early diagnosis of diabetes and the associated cardiovascular risk factors, and appropriate diabetes therapy including the use of glucose-lowering drugs and cardiovascular risk factor reductions, with the overall aim of reducing cardiovascular complications and mortality.
